scholarly journals Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial

2008 ◽  
Vol 62 (5) ◽  
pp. 1122-1129 ◽  
Author(s):  
M. Lafaurie ◽  
F. Collin ◽  
M. Bentata ◽  
M. Garre ◽  
C. Leport ◽  
...  
Keyword(s):  
Clinical Benefit ◽  
Haematological Improvement

918: Evaluation of the Clinical Benefit of Permixon and Tamsulosin in Severe BPH Patients – Permal Study Sub-Set Analysis

2004 ◽  
Vol 171 (4S) ◽  
pp. 243-244 ◽  
Author(s):  
Frans Debruyne ◽  
Peter Boyle ◽  
Remigio Vela-Navarrete ◽  
Fernando Calais Da Silva ◽  
Pierre Teillac ◽  
...  
Keyword(s):  
Clinical Benefit

Erythropoietin for HCV May Lack Clinical Benefit

2008 ◽  
Vol 41 (9) ◽  
pp. 52
Author(s):  
MICHELE G. SULLIVAN
Keyword(s):  
Clinical Benefit

Idiopathic venous thrombosis

2006 ◽  
Vol 26 (01) ◽  
pp. 52-54 ◽  
Author(s):  
P. A. Kyrle
Keyword(s):  
Chronic Disease ◽  
Venous Thrombosis ◽  
Vitamin K ◽  
Clinical Benefit ◽  
Plasma Levels ◽  
Vitamin K Antagonists ◽  
Antithrombin Deficiency ◽  
Optimal Duration ◽  
Risk Of Treatment

SummaryVenous thrombosis is a chronic disease with a recurrence rate of approximately 30% within 5-8 years. The optimal duration of secondary thromboprophylaxis in these patients entails balancing the risk of recurrence against the risk of treatment-associated bleeding. There is agreement that patients with a first idiopathic venous thrombosis should receive vitamin K antagonists for at least 3-6 months. Convincing trials showing a clinical benefit in terms of morbidity or mortality with respect to expansion of anticoagulation beyond 6 months are lacking. Nevertheless, some subgroups of patients with venous thrombosis may benefit from indefinite anticoagulation. Thus, patients with antithrombin deficiency, combined or homozygous defects, more than one unprovoked episode of thrombosis, the lupus anticoagulant or high factor VIII plasma levels are good candidates for long-term prevention.

Sirolimus-eluting Versus Bare Stents After Suboptimal Infrapopliteal Angioplasty for Critical Limb Ischemia: Enduring 1-year Angiographic and Clinical Benefit

2007 ◽  
Vol 14 (2) ◽  
pp. 241-250 ◽  
Author(s):  
Dimitris Siablis ◽  
Dimitris Karnabatidis ◽  
Konstantinos Katsanos ◽  
George C. Kagadis ◽  
Pantelis Kraniotis ◽  
...  
Keyword(s):  
Critical Limb Ischemia ◽  
Clinical Benefit ◽  
Limb Ischemia ◽  
Infrapopliteal Angioplasty

Mechanism of Action of Cherry Bark-containing Jumihaidokuto (Shi-Wei-Bai-Du-Tang) and Its Clinical Benefit in Patients with Acne Vulgaris

2014 ◽  
Vol 76 (2) ◽  
pp. 140-146
Author(s):  
Tsukasa TAKEMURA ◽  
Hiromi TOHNO ◽  
Satoshi YOMODA ◽  
Toshiki OKUBO
Keyword(s):  
Mechanism Of Action ◽  
Clinical Benefit ◽  
Acne Vulgaris
Sign in / Sign up

Export Citation Format

Share Document